Authors: Kvist, EE Al-Shurbaji, A Dahl, ML Nordin, C Alvan, G Stahle, L

Citation: Ee. Kvist et al., Quantitative pharmacogenetics of nortriptyline - A novel approach, CLIN PHARMA, 40(11), 2001, pp. 869-877

Authors: Alvan, G Bertilsson, L Dahl, ML Ingelman-Sundberg, M Sjoqvist, F

Citation: G. Alvan et al., Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation, DRUG META D, 29(4), 2001, pp. 580-585

Authors: Edlund, C Alvan, G Barkholt, L Vacheron, F Nord, CE

Citation: C. Edlund et al., Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora, J ANTIMICRO, 46(5), 2000, pp. 741-749

Authors: Phillips, K Howard, DA Bentley, MC Alvan, G

Citation: K. Phillips et al., Assessment of environmental tobacco smoke and respirable suspended particle exposures for nonsmokers in Basel by personal monitoring, ATMOS ENVIR, 33(12), 1999, pp. 1889-1904

Authors: Alvan, G Paintaud, G Wakelkamp, M

Citation: G. Alvan et al., The efficiency concept in pharmacodynamics, CLIN PHARMA, 36(5), 1999, pp. 375-389

Authors: Sandwall, P Lo, MW Jonzon, B Dalen, P Furtek, C Ritter, M Alvan, G McCrea, J Sjoqvist, F

Citation: P. Sandwall et al., Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19), EUR J CL PH, 55(4), 1999, pp. 279-283